Recurrent KRAS mutation is tested in mesonephric adenocarcinoma [50], and KRAS amplification and its mRNA expression are measured in early stage of recurrent endometrioid EC [51]. This evidence concerns the gene KRAS and mesonephric adenocarcinoma.